J.-F. Riou

Preclinical evaluation of docetaxel (Taxotere).

P. Vrignaud, M. Bissery, J. Riou, 1995, Seminars in oncology.

Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38.

J. Robert, J. Riou, H. Dodds, 1998, The Journal of pharmacology and experimental therapeutics.

The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II.

A. Larsen, J. Riou, J. Jardillier, 1993, Biochemical pharmacology.

Sequential modifications of topoisomerase I activity in a camptothecin-resistant cell line established by progressive adaptation.

G. Riou, S. Prost, J. Riou, 1993, Biochemical pharmacology.

Kinetics of lactone hydrolysis in antitumor drugs of camptothecin series as studied by fluorescence spectroscopy.

M. Manfait, G. Sockalingum, I. Chourpa, 1998, Biochimica et biophysica acta.

Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients.

J. Robert, S. Pond, J. Riou, 1996, Cancer research.

Preclinical evaluation of CPT-11 and its active metabolite SN-38.

F. Roquet, M. Bissery, J. Riou, 1996, Seminars in oncology.